Prehospital abciximab in st-segment elevation myocardial infarction results of the randomized, double-blind MISTRAL study

Circulation: Cardiovascular Interventions

Volumn 5, Issue 1, 2012, Pages 69-76

  Ohlmann, Patrick ^a   Reydel, Philippe ^b   Jacquemin, Laurent ^c,m   Adnet, Frédéric ^f   Wolf, Olivier ^d   Bartier, Jean Claude ^b   Weiss, Anne ^b   Lapostolle, Frédéric ^e   Gaultier, Cédric ^g   Salengro, Emmanuel ^g   Benamer, Hakim ^g   Guyon, Philippe ^h   Chevalier, Bernard ^h   Catan, Simon ^j   Ecollan, Patrick ^k   Chouihed, Tahar ⁱ   Angioi, Michael ⁱ   Zupan, Michel ^a   Bronner, François ^a   Bareiss, Pierre ^a   Steg, Gabriel ^k   Montalescot, Gilles ^l   Monassier, Jean Pierre ^c   Morel, Olivier ^a   more..

^a UNIVERSITÉ DE STRASBOURG   (France)

^b SAMU 67   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d CH Robert Boulin   (France)

^e SAMU 68   (France)

^f Hopital de Mulhouse   (France)

^g AVICENNE HOSPITAL   (France)

^h Clinique de la Roseraie   (France)

ⁱ CENTRE CARDIOLOGIQUE DU NORD   (France)

^j Hôpital Montfermeil   (France)

^k UNIVERSITÉ DE LORRAINE   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m BICHAT HOSPITAL   (France)

more..

Author keywords

Abciximab; Early medical intervention; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PLACEBO;

ADULT; ANGIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; EMERGENCY CARE; FEMALE; HEART INFARCTION SIZE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURGICAL WARD; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84859110711     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.961425     Document Type: Article

References (24)

1. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966. (Pubitemid 34983245)
2. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223-228. (Pubitemid 26031478)
3. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765-772. (Pubitemid 28135339)
4. Schroder R, Dissmann R, Bruggemann T, Wegscheider K, Linderer T, Tebbe U, Neuhaus KL. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24:384-391. (Pubitemid 24246537)
5. Claeys MJ, Bosmans J, Veenstra L, Jorens P, De Raedt H, Vrints CJ. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation. 1999;99:1972-1977. (Pubitemid 29183893)
6. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903. (Pubitemid 32553358)
7. van't Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372:537-546.
8. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, Parodi G, Fernandez-Pereira C, Moschi G, Bartorelli A, Santoro GM, Bolognese L, Colombo A. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1879-1885. (Pubitemid 37485558)
9. Rakowski T, Siudak Z, Dziewierz A, Birkemeyer R, Legutko J, Mielecki W, Depukat R, Janzon M, Stefaniak J, Zmudka K, Dubiel JS, Partyka L, Dudek D. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry. Am Heart J. 2009;158: 569-575.
10. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205-2217. (Pubitemid 351724450)
11. Montalescot G. Mechanical reperfusion: treat well, treat on time too. Lancet. 2008;372:509-510.
12. Schroder K, Wegscheider K, Zeymer U, Tebbe U, Schroder R. Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction. Lancet. 2001;358:1479-1486. (Pubitemid 33055698)
13. Ohlmann P, Monassier JP, Michotey MO, Berenger N, Jacquemin L, Laval G, Roul G, Schneider F. Troponin I concentrations following primary percutaneous coronary intervention predict large infarct size and left ventricular dysfunction in patients with ST-segment elevation acute myocardial infarction. Atherosclerosis. 2003;168:181-189. (Pubitemid 36555826)
14. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115: 256-265.
15. Bates ER. Revisiting reperfusion therapy in inferior myocardial infarction. J Am Coll Cardiol. 1997;30:334-342. (Pubitemid 27339310)
16. De Luca G, van't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J. 2005;26: 662-666. (Pubitemid 40516877)
17. Henriques JP, Zijlstra F, Ottervanger JP, de Boer MJ, van't Hof AW, Hoorntje JC, Suryapranata H. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002;23:1112-1117. (Pubitemid 35230716)
18. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009;30:2705-2713.
19. Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Moeckel M, Stone GW. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 2011;123:1745-1756.
20. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230. (Pubitemid 351724451)
21. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
22. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
23. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30.
24. Smit JJ, van Werkum JW, ten Berg J, Slingerland R, Ottervanger JP, Heestermans T, Dill T, Hamm C, van't Hof AW. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart. 2010;96:1815-1820.